# Sapphire 3 CTO Study

Study · id `cardio:ct-nct06358508` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06358508](<https://clinicaltrials.gov/study/NCT06358508>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06358508

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

## Technical summary

Registry record NCT06358508. Allocation not applicable; no masking; primary purpose treatment. Start 2024-11-06 (actual); primary completion 2025-10-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 170 participants (enrolled count; ClinicalTrials.gov record NCT06358508, source copy `cardio:ctgov-nct06358508-2026-01-12`, retrieved 2026-10-26)
- Started: 2024-11-06 (actual) (ClinicalTrials.gov record NCT06358508, source copy `cardio:ctgov-nct06358508-2026-01-12`, retrieved 2026-10-26)
- Primary completion: 2025-10-21 (actual) (ClinicalTrials.gov record NCT06358508, source copy `cardio:ctgov-nct06358508-2026-01-12`, retrieved 2026-10-26)
- Completion: 2025-10-21 (actual) (ClinicalTrials.gov record NCT06358508, source copy `cardio:ctgov-nct06358508-2026-01-12`, retrieved 2026-10-26)
- Countries: United States; Spain (ClinicalTrials.gov record NCT06358508, source copy `cardio:ctgov-nct06358508-2026-01-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06358508-2026-01-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sapphire 3 CTO Study
- Condition: Coronary Artery Disease
- Condition: Coronary Disease
- Condition: Myocardial Ischemia
- Condition: Heart Diseases
- Condition: Arteriosclerosis
- Condition: Cardiovascular Diseases
- Condition: Chronic Total Occlusion
- Condition: Chronic Total Occlusion of Coronary Artery
- Intervention (Device): Sapphire 3 Coronary Dilatation Catheter
- Lead sponsor: OrbusNeich
- Lead sponsor class: INDUSTRY
- Collaborator: Avania
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: OrbusNeich (`cardio:org-orbusneich`)
- Registry lists this organization as a collaborator: Avania (`cardio:org-avania`)

## Provenance

Content hash: 5da901c809f494e156547c56c267cd43aa4dbdeb0be8e3701a7648c0a98f2315
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
